Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shenyang Sunshine Pharmaceutical
Shenyang, Liaoning, China3sbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shenyang Sunshine Pharmaceutical, now part of 3SBio, is a leading Chinese biopharma with approved biologics (EPO, TPO, IFN, IL-2, and more). Key drugs are established leaders in China for hematologic and oncologic indications[3][7]. The company has ongoing clinical development and regulatory submissions for new biologic and antibody drugs.
- Therapeutic areas
- DermatologyInfectious DiseasesOphthalmologyOncologyPulmonologyHematology
- Modalities
- Monoclonal antibodyColony-stimulating factorSmall moleculeBiologicBiosimilarRecombinant protein
- Industry
- Biotech
02
Partnerships
AstraZeneca (Byetta/Bydureon China rights)CStone Pharmaceuticals (anti-PD-1 antibody nofazinlimab China rights)[4]Pfizer (licensing deals via 3SBio)[10]
Beyond the preview
Go deeper on Shenyang Sunshine Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenyang Sunshine Pharmaceutical.